Body surface area as a determinant of pharmacokinetics and drug dosing.
about
Long-term artificial sweetener acesulfame potassium treatment alters neurometabolic functions in C57BL/6J miceThe average body surface area of adult cancer patients in the UK: a multicentre retrospective studySafety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 miceEvaluation of five formulae for estimating body surface area of nigerian childrenCapecitabine: fulfilling the promise of oral chemotherapy.Calculation of body surface area via computed tomography-guided modeling in domestic rabbits (Oryctolagus cuniculus).Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.A Framework for Analyzing the Whole Body Surface Area from a Single View.Population-based input function and image-derived input function for [¹¹C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorderA phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancerLean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer.Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trialsChemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.Nutritional factors in ovarian cancer survival.Pharmacokinetic evaluation of pemetrexed.Effects of gender on capecitabine toxicity in colorectal cancer.Developing Exposure/Response Models for Anticancer Drug Treatment: Special ConsiderationsFixed Dosing of Monoclonal Antibodies in Oncology.A review of body composition and pharmacokinetics in oncology.Cardiac morphology and function reference values derived from a large subset of healthy young Caucasian adults by magnetic resonance imaging.Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.Population pharmacokinetics of liposomal daunorubicin in children.Prescribing oral chemotherapy.Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.Can docetaxel dosing be individualized based on cytochrome p450 activity?Relationship between diverse patient body size- and image acquisition-related factors, and quantitative and qualitative image quality in coronary computed tomography angiography: a multicenter observational study.High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based dose calculation.Critical Considerations in Anticancer Drug Development and Dosing Strategies: The Past, Present, and Future.Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer.Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines.
P2860
Q21132667-D4B1C4E8-EDE4-4A0E-9B8C-7F97E50FF1DCQ21142666-D13F44A9-376B-40AC-8902-82FB739302F9Q33829773-9363F57E-7E83-4BB9-8B5C-2FAAD5B46A2FQ34349192-D9C36E3B-DC56-4D40-9067-A59F06CC1E7AQ34606723-3F01D895-88E0-44B9-9292-144212A2BCF8Q34660785-155FBFFC-D65D-4CEE-ADF1-8FF8D9F668B3Q36019778-15363714-4121-4915-ABE0-33FE040D9EE5Q36104280-8DEB8865-11DB-4C44-B8DA-F860E4936C8FQ36218118-C74A51DD-81B7-469A-A564-10F6EEED50A8Q36237760-07A15DA6-3807-4151-8D46-E6E71E92FE31Q36319736-79B73671-6BAA-45BD-927F-5ABB06070590Q36614004-1F75FB9F-535E-4222-B993-59495F450266Q36797250-4E5ADE6D-AD07-42BC-AD3E-C10641720CE3Q36904564-66364A10-2185-4B52-8304-47CCF9F98EA8Q37034836-C58BB7DC-6DC6-44D7-BCE3-170C7C8F5D64Q37364612-B548A233-5AF7-4B31-BC4A-AB81375A7C8DQ37477083-ACAC43F8-18C7-4BCE-8FC0-5D196F674907Q37617204-96E2FCAF-DD6A-427D-831A-8A86330400D2Q37877715-4D95018D-97AE-44A9-8F5C-54AE6E0E308CQ38499473-3715B6CA-BD02-4605-B8CE-5B5CFED40509Q38557331-417C46F8-E8D8-47DC-AFF2-37E28D12BD68Q38654371-525486DF-8B63-47F2-AE15-A4A0FA1265A4Q38709340-B53FBB05-D6F9-42A4-B318-4D77C4079269Q40556464-EE31DB35-3F72-48E0-9B82-E6AE4E88F435Q41471506-B76C72E8-3A85-44ED-97EE-970759B2E10EQ42104275-3BC2D49B-0528-442E-9CCB-C5AA3DE3EEABQ42760004-A23DA305-FC30-4EFA-A846-34D76BA40E05Q42944289-2A1667B2-3630-4AA2-9517-C0A70C75CE19Q45117173-6E514109-4C79-4A7A-A961-6168EC7904C9Q46427740-CB2F77D4-73A8-4825-9567-131A72DBBA4EQ46787090-F3558C17-59B1-4326-94D0-072686374A25Q47298519-C6C7F79B-8866-4B99-BA84-1C5FB9A94090Q47385414-A3B51E61-4FA8-4493-BC17-6A3ACC70F9BCQ47943868-2A6CAAA7-AAC1-4936-9669-4AB1ECF63D76Q48099902-11D517D5-AD64-4E0A-94A5-8CF8CFBA60EEQ50677312-3788EE81-BD0C-4489-8A01-12126A3740B7Q52576799-71A607E3-92D8-4824-90CA-46D51A04B19BQ53449568-8489B83F-483D-469B-A084-4032CC382D48Q54380348-2AA8BEF7-C732-486A-AE1D-29C193F18547Q55196969-773915DF-6EE7-4A84-A17C-534E955B9D5B
P2860
Body surface area as a determinant of pharmacokinetics and drug dosing.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Body surface area as a determinant of pharmacokinetics and drug dosing.
@ast
Body surface area as a determinant of pharmacokinetics and drug dosing.
@en
Body surface area as a determinant of pharmacokinetics and drug dosing.
@nl
type
label
Body surface area as a determinant of pharmacokinetics and drug dosing.
@ast
Body surface area as a determinant of pharmacokinetics and drug dosing.
@en
Body surface area as a determinant of pharmacokinetics and drug dosing.
@nl
prefLabel
Body surface area as a determinant of pharmacokinetics and drug dosing.
@ast
Body surface area as a determinant of pharmacokinetics and drug dosing.
@en
Body surface area as a determinant of pharmacokinetics and drug dosing.
@nl
P356
P1476
Body surface area as a determinant of pharmacokinetics and drug dosing.
@en
P2093
P2888
P304
P356
10.1023/A:1010639201787
P577
2001-05-01T00:00:00Z
P6179
1044001232